Table I.
Metformin | ↓ HbA1c | ↓ PPG | Long-term efficacy | ↑ Hypo-glycemia | ↑ Fluid retention/heart failure | ↑Body weight | ↑ Bone fractures | Long-term safety | ↑ Gastro-intestinal side-effects |
---|---|---|---|---|---|---|---|---|---|
Plus sulfonylureas | +++ | + | – | +++ | – | ++ | – | + | – |
Plus repaglinide | ++ | ++ | + | ++ | – | ++ | – | + | + |
Plus thiazolidinediones | ++ | + | ++ | + | ++ | ++ | + | + | – |
Plus DPP-4/GLP-1 | ++ | ++ | ++ | + | – | – | – | ++ | + |
Plus α-glucosidase inhibitors | ++ | +++ | +++ | – | – | – | – | +++ | ++ |